Actionable news
All posts from Actionable news
Actionable news in VBLT: VASCULAR BIOGENICS Ltd,

VBL Therapeutics Data on VB-111 in Combination With Bevacizumab to be Presented at the Annual Meeting of the Society for Neuro-Oncology

TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that two presentations will be made on the company's lead oncology product, VB-111, a first-in-class, targeted, anti-angiogenic gene-therapy agent with applicability for multiple solid tumor indications, at the 2015 annual meeting of the Society for Neuro-Oncology, being held in San Antonio, Texas, November 19-22, 2015.

2015 Annual Meeting of the Society of Neuro-Oncology
Date: Friday, November 20, 2015
Time: 12:00pm - 1:30pm Central Time
Session: Satellite Symposium
Presentation Title: VB‐111, a Novel Gene Therapeutic for rGBM: From Bench to Pivotal Phase 3 GLOBE Trial
Location: Marriott Rivercenter, Salon GM
Date: Friday, November 20, 2015
Time: 7:30pm - 9:30pm Central Time
Presentation Title: Phase 2 Study of VB-111, an Anti-Cancer Gene Therapy, as Monotherapy Followed by Combination of VB-111 with Bevacizumab, in Patients with Recurrent Glioblastoma
Location: Henry B Gonzalez Convention Center, Ballroom B

About the Society for Neuro-Oncology

The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. Now in its nineteenth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

About VB-111

VB-111 is a novel, intravenously-administered, targeted...